C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, to discuss advancements in targeted protein degradation science and the development of new small-molecule medicines.
01/04/2024 - 07:00 AM
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11 at 9:00 am PST (12:00 pm EST).
A live webcast of the presentation can be accessed on the “Events & Presentations” page of the Investors section on the Company’s website at www.c4therapeutics.com . A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com .
Contacts:
Investors: Courtney Solberg Senior Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com
When will C4 Therapeutics present at the 42nd Annual J.P. Morgan Healthcare Conference?
C4 Therapeutics will present on January 11, 2024.
What is the focus of C4 Therapeutics' presentation at the conference?
The focus is on advancing targeted protein degradation science and developing new small-molecule medicines.
Where can the webcast of the presentation be accessed?
The webcast can be accessed on the 'Events & Presentations' page of the Investors section on the Company’s website at www.c4therapeutics.com.
How long will the webcast be available for replay?
The webcast will be archived on the C4T website for at least two weeks following the presentation.
CCCC Rankings
#5403 Ranked by Stock Gains
CCCC Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About CCCC
c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.